II. Precautions
- Complex patients with Atrial Fibrillation with Rapid Ventricular Rate (compensatory Tachycardia)
- Secondary cause for Atrial Fibrillation (Alcohol Withdrawal, decompensated COPD, Sepsis, CHF exacerbation)
- In these cases, serious active comorbidity is resulting in rapid rate and Atrial Fibrillation is incidental in these cases
- Focus on treating the underlying severe illness (e.g. Sepsis, CHF, COPD, Alcohol Withdrawal)
- High rate of adverse events when Atrial Fibrillation rate or rhythm control are used in these patients
- Scheuermeyer (2014) Ann Emerg Med S0196-0644(14)01298-0 +PMID:25441768 [PubMed]
- Secondary Atrial Fibrillation with Rapid Ventricular Rate may require primary management
- Although management of underlying cause is paramount, refractory instability may be due to the RVR
- May contribute to hemodynamic instability despite management of underlying cause (e.g. Sepsis)
- Diastolic Dysfunction may be challenging to manage, as rate significantly limits Cardiac Output
- May require Vasopressors, as well as cardioversion or Antiarrhythmic (e.g. Amiodarone)
- See hemodynamically unstable management as below
III. Management: Hemodynamically Unstable
- Criteria
- Rapid Heart Rate over 150 beats per minute
- Symptoms or signs of cardiovascular compromise
- In complex presentations, consider compensatory Tachycardia for secondary cause (see precautions above)
- Although immediate cardioversion is indicated in unstable primary Atrial Fib RVR, it may be harmful in secondary cause
- In the Peri-Arrest patient, electrical cardioversion may be the only initial option
- However, try to otherwise distinguish instability due to secondary cause if suspected (e.g. Sepsis)
- If Hypotension is due to Atrial Fibrillation with rapid rate, expect the patient to be cool
- Contrast with Sepsis with vasodilation, in which the patient's skin will be warm
- Expect typical rates for Atrial Fibrillation rapid ventricular response (130-140 if younger, 110 if older)
- Heart Rate of 160 suggests compensatory Tachycardia for secondary cause (e.g. Sepsis)
- Treating Sepsis with volume replacement and lowering Temperature should start to correct Tachycardia
- Consider differential diagnosis of irregularly irregular Supraventricular Tachycardia
- Atrial Fibrillation
- Consider ventricular preexcitation (e.g. WPW) in QRS Widening with varied QRS morphology
- Multifocal Atrial Tachycardia
- Atrial fluttter with variable atrioventricular conduction
- Atrial Fibrillation
- Be alert for Diastolic Dysfunction (HFpEF)
- Rapid ventricular rate and Hypotension may be made paradoxically worse with fluid bolus in HFpEF
- Make early use of Vasopressors (see below)
- Be cautious with fluid administration
- Dr. Jacob Lentz (2020) email communication 12/26/2020
- Vasopressors may be indicated in refractory Hypotension due to secondary cause
- Options
- Vasopressin increases vascular resistance, without increasing Heart Rate or contractility
- Norepinephrine may also be used without significantly increasing Tachycardia
- Phenylephrine (as Push Dose Pressor)
- Response
- If Heart Rate improves with a Vasopressor, then it is likely compensatory Tachycardia
- If Heart Rate does not improve with Vasopressor, then Atrial Fib RVR may be the cause of Hypotension
- Options
- Although immediate cardioversion is indicated in unstable primary Atrial Fib RVR, it may be harmful in secondary cause
-
Atrial Fibrillation Electrical Cardioversion
- See Synchronized Cardioversion
- Preferred Procedural Sedation with Ketamine or Etomidate (to avoid Hypotension)
- Consider Adenosine 6-12 mg rapid IV (if no delay)
- Use only if regular rate and unclear diagnosis (possible PSVT)
- Not effective in Atrial Flutter (but will slow rate for closer EKG rhythm evaluation)
- Perform optimization if possible prior to attempted cardioversion
- Correct Electrolyte abnormalities (e.g. Hypomagnesemia, Hypokalemia)
- Consider Antiarrhythmic such as Amiodarone 150 mg bolus IV prior to cardioversion
- Risk of worsening Hypotension
- Synchronized Cardioversion
- Monophasic dose: 200 joules synchronized (up to 360 joules)
- Biphasic dose: 150 joules synchronized (up to 200 joules)
- Anticoagulation
- Indications
- Atrial Fibrillation of unknown duration or >48 hours or
- Emergent, unstable cases requiring immediate cardioversion or
- High risk for CVA (e.g. prior TIA or CVA, Rheumatic Heart Disease, Mechanical Heart Valve)
- Many cardiologists recommend Anticoagulation after any electrical cardioversion
- Protocol
- Unfractionated Heparin or Low Molecular Weight Heparin at the time of cardioversion
- Warfarin (or other Anticoagulant such as Rivaroxaban) for 3-4 weeks after cardioversion
- Indications
-
Unstable Patient and Failed Electrical Cardioversion (or longstanding Atrial Fibrillation and unlikely to respond to cardioversion)
- Administer Vasopressor (e.g. Norepinephrine) to increase mean arterial pressure above 70-75 mmHg
- Titrate dosing as needed in response to Hypotension with the following agents
- Rate control agent options (choose one)
- Amiodarone 150 mg bolus IV (may be repeated up to 6 times)
- Esmolol infusion
- Diltiazem infusion (without bolus)
- Other measures
- Consider Magnesium 2 g IV
- Use only with caution in unstable, hypotensive patients
- Magnesium may increase vasodilation, and worsen Hypotension
- Consider Calcium Gluconate 2 g IV
- Consider prior to Diltiazem IV in Hypotension
- Consider Magnesium 2 g IV
- Administer Vasopressor (e.g. Norepinephrine) to increase mean arterial pressure above 70-75 mmHg
- References
- Weingart and Swaminathan in Herbert (2020) 20(1): 2-4
- Blackman et. al. (2020) EMDOcs, accessed 12/28/2020
IV. Management: Hemodynamically Stable
- Asymptomatic, hemodynamically stable patients with Heart Rate <110 to 120
- No emergency management required
- Manage precipitating conditions (e.g. holiday heart)
- Initiate or adjust Atrial Fibrillation Rate Control
- See Atrial Fibrillation Anticoagulation
- Symptomatic patients or Heart Rate >110 to 120
- Initiate Atrial Fibrillation Rate Control
-
Atrial Fibrillation Cardioversion to sinus rhythm
- See Atrial Fibrillation Cardioversion
- Conservative protocol for Safe Cardioversion Indications (CAEP)
- Adequate Anticoagulation for >3 weeks OR
- CHADS-65 >=2 AND onset <12 hours AND No stroke, TIA or valvular heart disease history OR
- CHADS-65 <2 AND onset <48 hours OR
- Negative transesophageal Echocardiography
- Stiell (2021) CJEM 23(5):604-10 +PMID: 34383280 [PubMed]
- Atrial Fibrillation less than 48 hours (acute Atrial Fibrillation)
- See Atrial Fibrillation Cardioversion for precautions
- Consider other CVA risks (e.g. CVA/TIA in last 6 months, Mechanical Heart Valve, rheumatic heart)
- Consider Heparin while considering cardioversion
- Consider early Atrial Fibrillation Cardioversion (esp. if age <65 years old)
- Many patients prefer this when presenting with recurrence of Atrial Fibrillation to the ED
- Atrial Fibrillation is uncomfortable (Dyspnea, Light Headedness)
- Rate control medications have adverse effects
- Endurance athletes with paroxysmal Atrial Fibrillation
- Self-cardioversion with aerobic Exercise (ventricular rates above a. fib rate) has been documented
- Paroxysmal Atrial Fibrillation is at increased risk in endurance athletes
- More common in males, and athletes who started at a young age
- Stergiou (2018) Curr Treat Options Cardiovasc Med 20(12):98 +PMID: 30367267 [PubMed]
- Atrial Fibrillation more than 48 hours
- See Atrial Fibrillation Anticoagulation
- Protocol
- Warfarin (or other approved Anticoagulant/DOAC) for 3 weeks before cardioversion
- Atrial Fibrillation Cardioversion
- Continue Warfarin (or other approved Anticoagulant) for 4 weeks after cardioversion
- Early cardioversion may be acceptable if cleared with Transesophageal Echocardiogram (TEE) first
- Normal TEE does not exclude all Thromboembolism risk in anticoagulated patients
- See Atrial Fibrillation Cardioversion for precautions
V. Disposition: Hospitalization Indications
- Atrial Fibrillation with Rapid Ventricular Rate
- Requiring continuous intravenous Atrial Fibrillation Rate Control (e.g. Diltiazem infusion)
- Congestive Heart Failure (CHF)
- Angina, Acute Coronary Syndrome or Myocardial Infarction
- Hypotension
- Serious comorbidity
- Other possible indications for hospitalization
- Elderly
- Unreliable follow-up
- Structural heart disease
- New onset Atrial Fibrillation hospitalization indications
- Acute Coronary Syndrome symptoms (typical symptoms)
- Coronary Artery Disease suspected as cause of Atrial Fibrillation trigger
- Patients at higher risk of coronary disease who present with atypical ACS symptoms
- Elderly
- Diabetes Mellitus
- Acute Coronary Syndrome symptoms (typical symptoms)
VI. Disposition: Emergency Department Observation Unit
- Indications
- Atrial Fibrillation onset within last 48 hours AND
- Normotensive patients (SBP > 90 mmHg) AND
- No Acute Coronary Syndrome, Heart Failure or other comorbidity AND
- Heart Rate <130 after IV rate control
- Contraindications
- Chest Pain
- Ischemic EKG changes
- Respiratory distress
- Fluid Overload
- Hypoxia
- Hypotension
- Decompensated significant condition (e.g. Sepsis, GI Bleed)
- New onset Acute Kidney Injury
- Pregnancy
- Lack of close follow-up
- Unable to comply with medication management
- Discharge goals (choose one of three options)
- Spontaneous cardioversion on rate control agent OR
- Electrical Cardioversion (consider TEE first) OR
- Rate control on oral nodal blockade agent (e.g. Metoprolol, Diltiazem) for at least 1-2 hours
- Heart Rate <100-100 bpm at rest (<110-120 bpm with activity)
-
Anticoagulation
- CHADS2-VASc Score 2 or more indicates oral Anticoagulants (Warfarin or DOAC)
- HAS-BLED Score 3 or more suggests high risk of bleeding
- Expert opinion: Anticoagulation (Warfarin or DOAC) for 3 weeks after electrical cardioversion
- Factor comorbidity (hepatic or renal disease) into Anticoagulant selection
- ED observation unit protocol should include decision tools for Anticoagulant selection
- Education
- Medication Compliance
- Drug Interactions (and dietary restrictions)
- Anticoagulant Safety
- Avoiding Trauma and identifying signs, symptoms of bleeding
- Discharge from observation
- Established follow-up within 3-5 days
- Prescriptions for 30 day supply for lowest effective dose of rate control agent
- Anticoagulation agent prescription and follow-up with Anticoagulation clinic
- Efficacy
- Successful discharge to home in 80% of cases (20% require inpatient care)
- Shortens mean hospital stay from 50 hours to 13 hours
- References
- Davenport and Baugh (2018) Crit Dec Emerg Med 32(7): 15-24
- Decker (2008) Ann Emerg Med 52(4): 322-8 [PubMed]
VII. Disposition: Emergency Discharge Plan
- Interventions
- See Atrial Fibrillation Anticoagulation
- See Atrial Fibrillation Rate Control
- Anticoagulation, if indicated is often initiated prior to ED discharge
- Abstain from Alcohol, Caffeine and other potential exacerbating factors
- Consider cardiology Consultation (see indications below)
- Discharge Indications
- Asymptomatic (or CCS-SAF Scale 0-3) AND
- Heart Rate <110 beats per minute AND
- Hemodynamically stable (e.g. systolic Blood Pressure >90/60) AND
- No indications for hospitalization (see above)
- Follow-up
- Consider arranging cardiology follow-up
- Primary care follow-up
- Anticoagulation clinic follow-up
- Safety of emergency department discharge after cardioversion
- Discharge rates after cardioversion: 86-100%
- Return rate within 1 week: 10%
- Burton (2004) Ann Emerg Med 44(1): 20-30 [PubMed]
- Jacoby (2005) J Emerg Med 28(1): 27-30 [PubMed]
- Lo (2006) Emerg Med J 23(1): 51-3 [PubMed]
- von Besser (2011) Ann Emerg Med 58(6):517-20 +PMID:22098994 [PubMed]
VIII. Disposition: Cardiology Consultation indications
- Patient chronically managed with Atrial Fibrillation Rhythm Control
- Atrial Fibrillation with refractory rapid ventricular rate
- Structural heart disease (e.g. valvular heart disease, Congenital Heart Disease)
- Wolff-Parkinson-White Syndrome (WPW Syndrome) or other accessory pathway
- Decompensated Congestive Heart Failure or Coronary Artery Disease
IX. References
- Casaletto (2014) Crit Dec Emerg Med 28(4): 10-19
- Orman and Berg in Herbert (2016) EM:Rap 16(2): 6-10
- Stiell (2011) Canadian J Cardiol 27(1): 38-46 [PubMed]
- Wann (2011) Circulation 123(1): 104-23 [PubMed]
- King (2002) Am Fam Physician 66(2):249-56 [PubMed]
- Gutierrez (2011) Am Fam Physician 83(1): 61-8 [PubMed]
- Falk (2001) N Engl J Med 344:1067-78 [PubMed]
- Li (1998) Emerg Med Clin North Am 16:389-403 [PubMed]
- King (2002) Am Fam Physician 66:249-56 [PubMed]